New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12 Laura MasieroWilliam D. FiggElise C. Kohn OriginalPaper Pages: 23 - 35
Clinical trials of anti-vascular agent group B Streptococcus toxin (CM101) Adrian L. Harris OriginalPaper Pages: 36 - 37
On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans Ram SasisekharanSteffen ErnstGanesh Venkataraman OriginalPaper Pages: 45 - 54
Novel forms of acidic fibroblast growth factor-1 are constitutively exported by β tumor cell lines independent from conventional secretion and apoptosis Gerhard ChristoforiSusanne Luef OriginalPaper Pages: 55 - 70
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications Masakazu ToiMassimo GionGiampietro Gasparini OriginalPaper Pages: 71 - 83
A molecular and genetic analysis of renalglomerular capillary development Siobhan LoughnaPatricia HardmanAdrian S Woolf OriginalPaper Pages: 84 - 101
Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice Francesco SolaAnna GualandrisMarco Presta OriginalPaper Pages: 102 - 116
Distinct capillary density and progression promoted by vascular endothelial growth factor-A homodimers and heterodimers Lucia MorbidelliRalf BirkenhaegerMarina Ziche OriginalPaper Pages: 117 - 130